#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fallopian tube cancer Henoch-Schonlein purpura Oesophageal adenocarcinoma stage III Soft tissue necrosis Autoimmune hepatitis Congenital generalised lipodystrophy Drug eruption Neurodermatitis Hypoparathyroidism Ductal adenocarcinoma of pancreas Alport's syndrome Macular telangiectasia C3 glomerulopathy Pleomorphic liposarcoma Fatty acid oxidation disorder More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Basic Information Pelizaeus-Merzbacher disease – Diagnostics Loeys-Dietz syndrome – Trials in Disease Shprintzen-Goldberg syndrome – Diagnostics Leiomyosarcoma metastatic – Treatment Marginal zone lymphoma refractory – Treatment Glycogen storage disease type II – Trials in Disease Osteosarcoma metastatic – Basic Information Uterine leiomyosarcoma – Diagnostics Sarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Selgantolimod Elafibranor Pal1-15 Acetate Moxifloxacin Hydrochloride Ab-729 Dronabinol Midazolam S-241656 Etavopivat Mk-1942 Regn7257 L-PROLINE Levamlodipine Succinate Bifikafusp Alfa Topotecan Pentixafor GOCATAMIG HUMAN PLASMA Posenacaftor Povidone, Iodinated More therapies…

    Learn about Your Condition

    Metastatic malignant melanoma Vulval cancer Leukoencephalopathy Colitis ulcerative Angiosarcoma recurrent Acoustic neuroma Perineal injury Hypothyroidism Liver transplant rejection Retinopathy proliferative Premature baby Iron deficiency Conjunctivitis allergic Bronchitis Eczema More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Somogy Varmegyei Kaposi Mor Oktato Korhaz

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Tallian Gyula Utca 20-32, Kaposvar, 7400, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    • Pembrolizumab
    Belgium Bulgaria Croatia Czechia Estonia Finland +14

  • Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Left ventricular failure
    • Cardiac failure acute
    • Cardiac failure chronic
    Investigated Drugs:
    • Cdr132L
    • Cdr132L Sodium
    Czechia Germany Greece Hungary The Netherlands Poland +1

  • Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Danazol
    • Hydroxycarbamide
    • Pacritinib
    Bulgaria Czechia France Hungary Italy Poland +2

  • Study on the Effectiveness and Safety of MC2-25 Cream for Itching in Chronic Kidney Disease Patients

    Not recruiting

    2 1
    Investigated Diseases:
    • Chronic kidney disease-associated pruritus
    Investigated Drugs:
    • Alanyl Glutamine
    Germany Hungary Poland

  • Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Asundexian
    • Apixaban
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study on the Safety and Efficacy of PF-06835375 and Diphenhydramine Hydrochloride for Adults with Moderate to Severe Primary Immune Thrombocytopenia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Pf-06835375
    Czechia Hungary Poland

  • Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Seladelpar
    Austria Belgium Czechia France Germany Greece +6

  • Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

    Not recruiting

    3 1
    Investigated Drugs:
    • Obicetrapib
    Bulgaria Croatia Czechia Denmark Finland Germany +7

  • Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Olaparib
    • Carboplatin
    • Gemcitabine
    France Germany Hungary Ireland Poland Spain
Previous Page
1 … 10 11 12

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!